$0.97
1.04% today
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US71715X2036
Symbol
PMCB

PharmaCyte Biotech Inc Stock price

$0.97
-0.02 1.96% 1M
-0.69 41.57% 6M
-0.60 38.22% YTD
-0.89 47.85% 1Y
-1.63 62.69% 3Y
-17.03 94.61% 5Y
-143.03 99.33% 10Y
-314.03 99.69% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.01 1.04%
ISIN
US71715X2036
Symbol
PMCB
Industry

Key metrics

Basic
Market capitalization
$6.5m
Enterprise Value
$-10.2m
Net debt
positive
Cash
$16.8m
Shares outstanding
6.9m
Valuation (TTM | estimate)
P/E
0.8 | -
P/S
- | -
EV/Sales
- | -
EV/FCF
4.5
P/B
0.2
Financial Health
Equity Ratio
66.0%
Return on Equity
-43.6%
ROCE
-15.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
- | -
EBIT
$-6.5m | -
Net Income
$8.6m | -
Free Cash Flow
$-2.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-3.9% | -
Net Income
158.2% | -
Free Cash Flow
-7.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$1.2
FCF per Share
$-0.3
Short interest
0.2%
Employees
2
Rev per Employee
$0.0
Show more

Is PharmaCyte Biotech Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

PharmaCyte Biotech Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a PharmaCyte Biotech Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a PharmaCyte Biotech Inc forecast:

Hold
50%
Sell
50%

Financial data from PharmaCyte Biotech Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jan '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.10 4.10
30% 30%
-
- Research and Development Expense 0.41 0.41
3% 3%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -6.50 -6.50
4% 4%
-
Net Profit 8.63 8.63
158% 158%
-

In millions USD.

Don't miss a Thing! We will send you all news about PharmaCyte Biotech Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PharmaCyte Biotech Inc Stock News

Neutral
Business Wire
2 days ago
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), today announced the closing of its previously announced $7 million financing. As of April 30, 2025, PharmaCyte had approximately $15.5 million in cash and also holds over $30 million of securities as reflected in the Company's most recent 10K. With the addition of the $7 million in proceeds from ...
Neutral
Business Wire
4 days ago
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) announced today that it has entered into a securities purchase agreement for a $7.0 million financing with existing investors involving the sale of 7,000 shares of its newly designated Series C convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible in...

Company Profile

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

Head office United States
CEO Joshua Silverman
Employees 2
Founded 1996
Website pharmacyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today